Lakewood-Amedex Biotherapeutics Inc. (LABT)
NASDAQ: LABTHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
LABT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.88M
- EPS (TTM)
- -$8.83
- Dividend yield
- None
- 52-week range
- 0.76 – 98.20
- Day range
- 0.78 – 0.8254
- Volume / Avg
- 214.58K / 2.50M
- Beta
- —
- Shares outstanding
- 2.37M
52-week range
LABT stock today
Lakewood-Amedex Biotherapeutics (LABT) closed at $0.792 on Oct 8, down 6.80% (-$0.0578), versus the S&P 500's 0.47% decline. Trading was light, with 214.58K shares changing hands, about 9% of the average daily volume. Shares are 99.2% below their 52-week high of $98.20 and 4.2% above the 52-week low of $0.76, near the bottom of the past year's range.
Lakewood-Amedex Biotherapeutics has posted a net loss over the last twelve months (EPS of -$8.83), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Lakewood-Amedex Biotherapeutics
Company profileLakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Kelvin Cooper Ph.D.
- Headquarters
- University Park, FL
- Employees
- 5
- Website
- lakewoodamedex.com
Analyst forecast
ForecastConsensus
strong_buy
Avg. price target
$12.00+1415.15%
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Lakewood-Amedex Biotherapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ARTLArtelo Biosciences Inc. | 3.37 | -1.17% | $1.85M | vs LABT |
| VBIOValion Bio Inc. | 2.21 | +0.91% | $1.96M | vs LABT |
| EDVAEndovia Health Sciences Inc. | 0.1599 | -3.09% | $1.77M | vs LABT |
| CRISCuris Inc. | 0.7094 | -3.69% | $1.72M | vs LABT |
| OGENOragenics Inc. | 0.463 | -7.38% | $2.09M | vs LABT |
| SCNIScinai Immunotherapeutics Ltd. ADR | 1.21 | +7.08% | $1.64M | vs LABT |
| GNPXGenprex Inc. | 2.75 | +4.96% | $2.25M | vs LABT |
| TCRTAlaunos Therapeutics Inc. | 0.781 | -6.70% | $2.29M | vs LABT |
Indexes, lists and sector
Appears in lists
Lakewood-Amedex Biotherapeutics stock FAQ
What is Lakewood-Amedex Biotherapeutics's stock price today?
LABT last traded at $0.792 as of Oct 8, 4:00 PM EDT, down 6.80% on the day. Prices are delayed at least 15 minutes.
Who is Lakewood-Amedex Biotherapeutics's CEO?
Dr. Kelvin Cooper Ph.D. is the chief executive officer of Lakewood-Amedex Biotherapeutics Inc., which has about 5 employees.
What is the LABT 52-week high?
The 52-week high for LABT is $98.20 and the 52-week low is $0.76. The stock is currently 99.2% below its high.